The latest price list of capmatinib

is a MET inhibitor for non-small cell lung cancer (NSCLC). It not only provides a new treatment option for NSCLC patients carrying MET exon 14 skipping mutations, but its efficacy and safety are also supported by clinical studies. There are currently three versions of capmatinib, with different prices. The original drug is expensive and the generic drug is cheap.

Price list of capmatinib

1. Original drug: According to the latest information, the price of capmatinib varies in different countries and regions. In the United States, the price of capmatinib is relatively high, which places a financial burden on many patients. The original drug capmatinib produced by Novartis is priced at around $12,500 for 200mg*60 tablets.

2. Generic drugs: With the launch of generic drugs and approval in different countries and regions, the price of capmatinib is expected to be adjusted, allowing more patients to obtain this treatment. It is understood that the generic capmatinib produced by Lucius Pharmaceutical Factory in Laos sells for about $2,650 per box of 200mg*60 tablets. Capmatinib produced by Everest Pharmaceutical Factory in Bangladesh has a box size of 200mg*56 tablets and is priced at about $3,600 per box.

The situation of capmatinib in China

In China, capmatinib has submitted a marketing application to the Center for Drug Evaluation (CDE) of the State Food and Drug Administration and has been accepted. This means that capmatinib is expected to be officially launched in China in the near future, providing a new treatment option for domestic NSCLC patients

. In addition, capmatinib has been included in the second batch of catalog of clinically urgently imported drugs and medical devices from Hong Kong and Macao in the Guangdong-Hong Kong-Macao Greater Bay Area in 2022, which provides some patients with the opportunity to use capmatinib in advance.

Capmatinib, as an effective MET inhibitor, provides new hope for patients with non-small cell lung cancer. With the acceptance of its marketing application in China and possible medical insurance policy support, the price of capmatinib is expected to be further adjusted. This will allow more patients to have access to this advanced treatment, improving their quality of life and survival.